Share on StockTwits

Shares of Hemispherx BioPharma, (NYSE:HEB) were the recipient of a significant decline in short interest during the month of August. As of August 15th, there was short interest totalling 1,072,995 shares, a decline of 5.6% from the July 31st total of 1,136,132 shares, Analyst Ratings Network reports. Approximately 0.6% of the shares of the stock are sold short. Based on an average daily trading volume, of 468,969 shares, the days-to-cover ratio is currently 2.3 days.

Shares of Hemispherx BioPharma, (NYSE:HEB) opened at 0.2725 on Thursday. Hemispherx BioPharma, has a 1-year low of $0.19 and a 1-year high of $0.55. The stock’s 50-day moving average is $0. and its 200-day moving average is $0.33. The company’s market cap is $51.8 million.

Hemispherx Biopharma, Inc (NYSE:HEB) is a specialty pharmaceutical engaged in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.